| Literature DB >> 35238788 |
Wui Ip1, Priya Prahalad1, Jonathan Palma2, Jonathan H Chen3,4.
Abstract
BACKGROUND: Millions of people have limited access to specialty care. The problem is exacerbated by ineffective specialty visits due to incomplete prereferral workup, leading to delays in diagnosis and treatment. Existing processes to guide prereferral diagnostic workup are labor-intensive (ie, building a consensus guideline between primary care doctors and specialists) and require the availability of the specialists (ie, electronic consultation).Entities:
Keywords: EHR; algorithm; algorithm development; algorithm validation; automation; clinical decision support; electronic health records; machine learning; patient needs; prediction; recommender system; specialty consultation
Year: 2022 PMID: 35238788 PMCID: PMC8931647 DOI: 10.2196/30104
Source DB: PubMed Journal: JMIR Med Inform
Figure 1Algorithm training and construction of the item co-occurrence matrix.
Figure 2Algorithm evaluation using the test set.
Figure 3Evaluation of algorithm output by practicing endocrinologists. TSH: thyroid stimulating hormone.
Recommender algorithm performance in the test set. Precision and recall were calculated at k=4, given that 4 is the average number of workup orders.
|
| Recommendera | Endocrine prevalenceb | Outpatient prevalencec | Randomd |
| Precisione (%; 95% CI) | 48 (45-52) | 37 (34-40) | 10 (8-12) | 2 (2-3) |
| Recallf (%; 95% CI) | 39 (36-42) | 27 (24-29) | 5 (4-6) | 2 (1-3) |
| AUCg (95% CI) | 0.95 (0.95-0.96) | 0.88 (0.87-0.89) | 0.64 (0.62-0.66) | 0.49 (0.47-0.5) |
aRecommender: ranking workup orders using the recommender algorithm.
bEndocrine prevalence: ranking workup orders using the percentage of patients who had the orders in the endocrine referral cohort () training set.
cOutpatient prevalence: ranking workup orders using the percentage of patients who had the orders among all outpatients ().
dRandom: random ranking of workup orders.
ePrecision: positive predictive value (proportion of predictions that were correct).
fRecall: sensitivity (proportion of correct items that were predicted).
gAUC: area under the receiver operating characteristic curve.
Estimated percentages of patients with initial workup completed before specialty visits and mean Likert scale score of how helpful (5: extremely helpful; 1: not helpful at all) it is to have initial workup completed before specialty visits.
|
| Value, mean (SD) | |
|
| ||
|
| Abnormal thyroid studies | 49 (21) |
|
| Obesity | 45 (20) |
|
| Amenorrhea | 37 (18) |
|
| ||
|
| Abnormal thyroid studies | 4.2 (0.8) |
|
| Obesity | 3.3 (0.9) |
|
| Amenorrhea | 4.1 (0.8) |
Top recommendations for patients referred for high thyroid stimulating hormone (TSH; commonly due to hypothyroidism), low TSH (commonly due to hypothyroidism), obesity, and amenorrhea.
| Orders | PPVa (%) | Relative ratiob | Endocrine prevalencec (%) | Outpatient prevalenced (%) | Percent of endocrinologist considered appropriate | |
|
| ||||||
|
| TSHf | 60.9 | 1.0 | 61.7 | 17.1 | 92 |
|
| Free thyroxinef | 60.3 | 1.2 | 56.8 | 7.5 | 100 |
|
| Thyroglobulin antibodyf | 41.7 | 3.7 | 12.8 | 0.5 | 92 |
|
| Thyroperoxidase antibodyf | 39.1 | 3.2 | 13.7 | 1.0 | 92 |
|
| Vitamin D level | 9.3 | 0.3 | 31.4 | 8.1 | 0 |
|
| Serum cortisol | 8.6 | 0.7 | 11.3 | 0.7 | 0 |
|
| ||||||
|
| TSHh | 61.5 | 1.0 | 61.7 | 17.1 | 75 |
|
| Free thyroxineh | 57.7 | 1.0 | 56.8 | 7.5 | 100 |
|
| Thyroglobulin antibodyh | 50.0 | 4.0 | 12.8 | 0.5 | 67 |
|
| Thyroperoxidase antibodyh | 46.2 | 3.4 | 13.7 | 1.0 | 58 |
|
| Total tri-iodothyronineh | 42.3 | 16.1 | 3.0 | 0.7 | 92 |
|
| Comprehensive metabolic panel | 26.9 | 0.5 | 53.8 | 23.1 | 8 |
|
| ||||||
|
| Hemoglobin A1cj | 40.2 | 1.9 | 22.5 | 12.5 | 100 |
|
| TSH | 28.0 | 0.4 | 61.7 | 17.1 | 75 |
|
| Free thyroxine | 25.6 | 0.4 | 56.8 | 7.5 | 42 |
|
| Comprehensive metabolic panelj | 25.6 | 0.5 | 53.8 | 23.1 | 92 |
|
| Lipid panelj | 25.0 | 1.4 | 18.3 | 12.9 | 100 |
|
| Vitamin D level | 20.7 | 0.6 | 31.4 | 8.1 | 42 |
|
| ||||||
|
| Prolactinl | 41.4 | 4.8 | 8.9 | 0.4 | 92 |
|
| Luteinizing hormonel | 37.9 | 2.2 | 17.5 | 0.9 | 100 |
|
| Follicle stimulating hormonel | 34.5 | 2.1 | 16.5 | 1.7 | 100 |
|
| Estradiol | 27.6 | 4.7 | 6.1 | 0.4 | 100 |
|
| 17 Hydroxy-progesterone | 24.1 | 2.5 | 9.7 | 0.2 | 100 |
|
| Dehydroepi-androsterone sulfate | 17.2 | 2.2 | 8.0 | 0.4 | 92 |
aPPV: positive predictive value.
bRelative ratio: the ratio of the probability of the order given the query item to the probability of the order given the lack of the query item.
cEndocrine prevalence: the percentage of patients who had the orders in the endocrine referral cohort ().
dOutpatient prevalence: the percentage of patients who had the orders among all outpatients ().
eThe top four orders are considered clinically appropriate by almost all of the endocrinologists and are recommended based on published guidelines. The fifth and sixth recommended items have relatively low PPV.
fRecommended based on guidelines [36].
gHere, the top five orders are considered clinically appropriate by most endocrinologists and published guidelines.
hRecommended based on guidelines [37].
iHemoglobin A1c, lipid panel, and comprehensive metabolic panel are considered clinically appropriate both by the endocrinologists and published guidelines.
jRecommended based on guidelines [35].
kThe top six orders are considered clinically appropriate by almost all of the endocrinologists. The top three are also recommended based on published literature.
lRecommended based on published literature [30].